Jason Beckwith, PhD, highlights an imminent 'talent singularity' in biomanufacturing expected by 2028, where demand for skilled professionals will outpace supply. The industry faces shortages due to gaps in university training relevant to biopharma needs and technological evolution. Strategies proposed include cross-recruitment from other sectors, enhanced retention, and upskilling. Beckwith is collaborating with NIBRT and UCL to map future skill requirements, emphasizing competitive compensation to mitigate talent loss.